AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30

ANAVEX LIFE SCIENCES CORP.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 28, 2026

$1.25−0.06 (-4.58%)

Close on Oct 19, 2026

Market cap: $116.12B
P/E (TTM): –
Dividend yield: –

ANAVEX LIFE SCIENCES CORP. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q3 2026 2026-06-30	TTM Q2 2026 2026-03-31	TTM Q1 2026 2025-12-31	TTM FY 2025 2025-09-30	TTM Q3 2025 2025-06-30	TTM Q2 2025 2025-03-31	TTM Q1 2025 2024-12-31	TTM FY 2024 2024-09-30	TTM Q3 2024 2024-06-30	TTM Q2 2024 2024-03-31	TTM Q1 2024 2023-12-31	TTM FY 2023 2023-09-30	TTM Q3 2023 2023-06-30	TTM Q2 2023 2023-03-31	TTM Q1 2023 2022-12-31	TTM FY 2022 2022-09-30	TTM Q3 2022 2022-06-30	TTM Q2 2022 2022-03-31	TTM Q1 2022 2021-12-31	TTM FY 2021 2021-09-30	TTM Q3 2021 2021-06-30	TTM Q2 2021 2021-03-31	TTM Q1 2021 2020-12-31	TTM FY 2020 2020-09-30	TTM Q3 2020 2020-06-30	TTM Q2 2020 2020-03-31	TTM Q1 2020 2019-12-31	TTM FY 2019 2019-09-30	TTM Q3 2019 2019-06-30	TTM Q2 2019 2019-03-31	TTM Q1 2019 2018-12-31	TTM FY 2018 2018-09-30	TTM Q3 2018 2018-06-30	TTM Q2 2018 2018-03-31	TTM Q1 2018 2017-12-31	TTM FY 2017 2017-09-30	TTM Q3 2017 2017-06-30	TTM Q2 2017 2017-03-31	TTM Q1 2017 2016-12-31	TTM FY 2016 2016-09-30
Research & Development	–	26	32	38	42	44	44	42	40	39	40	44	45	44	41	38	36	36	34	33	30	27	27	25	24	23	23	22	22	19	16	13	13	12	11	11	10	9.06	7.66	7.25
Selling, General & Admin	10	12	13	14	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	12	13	14	13	11	11	11	11	11	11	12	13	13	13	13	12	11	11	9.02	7.54	6.49	5.98	5.86	6.09	6.10	6.44	6.85	6.69	6.92	6.35	5.99	5.87	5.65	5.28	5.01	6.86	6.59	6.57	8.33
Operating Expenses	17	39	45	51	55	55	55	53	51	50	52	56	58	57	55	51	48	47	44	42	-25	-28	-29	-31	30	29	29	29	29	26	23	19	19	18	17	16	17	16	14	16
Operating Income	-17	-39	-45	-51	-55	-55	-55	-53	-51	-50	-52	-56	-58	-57	-55	-51	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	4.37	4.50	4.67	5.03	6.67	7.84	8.60	9.88	9.67	9.57	8.62	8.26	7.02	4.91	4.89	3.37	2.84	3.92	3.63	4.36	5.24	5.60	5.31	4.83	4.03	3.04	3.45	2.89	2.48	3.60	2.67	2.15	1.87	0.21	2.27	2.28	2.31	2.26	0.34	0.88
Pretax Income	–	–	–	–	–	–	–	-43	-41	-40	-43	-47	-51	-52	-50	-48	-45	-43	-41	-38	-32	-28	-27	-26	-26	-26	-26	-26	-26	-23	-20	-17	-17	-18	-14	-13	-15	-13	-14	-15
Net Income	-13	-34	-40	-46	-48	-47	-46	-43	-42	-41	-43	-48	-52	-53	-50	-48	-45	-43	-41	-38	-32	-28	-28	-26	-26	-26	-26	-26	-26	-23	-20	-17	-17	-18	-14	-13	-15	-13	-14	-15
EPS (Basic)(per share)	-0.15	-0.39	-0.46	-0.54	-0.57	-0.55	-0.55	-0.52	-0.50	-0.50	-0.54	-0.60	–	–	–	–	–	–	–	–	-0.48	-0.45	-0.45	-0.45	-0.46	-0.48	-0.51	-0.54	-0.55	-0.48	-0.44	-0.39	-0.38	-0.36	-0.29	-0.33	-0.34	-0.36	-0.38	-0.42
EPS (Diluted)(per share)	-0.15	-0.39	-0.46	-0.54	-0.57	-0.55	-0.55	-0.52	-0.50	-0.50	-0.54	-0.60	–	–	–	–	–	–	–	–	-0.48	-0.45	-0.45	-0.45	-0.46	-0.48	-0.51	-0.54	-0.55	-0.48	-0.44	-0.39	-0.38	-0.36	-0.29	-0.33	-0.34	-0.36	-0.38	-0.42
Shares Outstanding (Basic, Weighted)(shares)	23,241	21,412	21,410	85	21,409	85	84	83	83	82	81	80	–	–	–	–	–	–	–	–	–	63	61	58	56	54	51	49	47	46	45	45	44	43	42	41	39	38	36	35
Shares Outstanding (Diluted, Weighted)(shares)	23,292	21,412	21,410	85	21,409	85	84	83	83	82	81	80	–	–	–	–	–	–	–	–	–	63	61	58	56	54	51	49	47	46	45	45	44	43	42	41	39	38	36	35
Net Interest Income	4.21	4.21	4.36	4.68	5.44	6.16	6.71	7.32	7.52	7.55	7.26	6.52	5.27	3.67	2.21	0.95	0.25	0.03	0.03	0.03	0.03	0.07	0.13	0.18	0.22	0.19	0.18	0.21	0.25	0.33	0.30	0.26	0.21	0.13	0.11	0.09	0.05	0.03	0.01	0.01

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -43.1%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1032.70
Dividend yield: –